Scarica l'app Stockscreener
625.11
0.24%
1.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharma strengthens its position in biotech. Focus on long-term growth and innovation - AD HOC NEWS
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program - BioSpace
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA selects seven companies including Eli Lilly and Regeneron for accelerated manufacturing review pilot - grafa.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Regeneron opens the week with analyst focus, shares on NASDAQ radar - AD HOC NEWS
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Insider Monkey
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why - Insider Monkey
How the president of Regeneron pursued his American dream - New York Post
Regeneron clears key moving averages, shares trade below consensus targets - Ad-hoc-news.de
Pictet Asset Management Holding SA Sells 30,616 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The EYLEA injection from Regeneron Pharmaceuticals Inc.high-dose eye therapy pushes into diabetic - Ad-hoc-news.de
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron myasthenia gravis therapy undergoes US and EU review - MSN
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance - Investorideas.com
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX) - The Globe and Mail
Aethlon Medical tracks Ebola outbreak, readies Hemopurifier talks - Stock Titan
Louisiana State Employees Retirement System Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron highlights robust pipeline progress, shares trade in a neutral technical range - Ad-hoc-news.de
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – GETTEX:RGO - TradingView
Price to earnings forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
The EYLEA Injection from Regeneron Pharmahigh-dose eye therapy targets chronic retinal disease - Ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:REGN) - TradingView
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast - The Manila Times
Regeneron schedules July 30 earnings call and webcast - Stock Titan
REGNUS Forecast — Price Target — Prediction for 2027 - TradingView
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $788 - Moomoo
Assenagon Asset Management S.A. Has $160.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion - The Business Journals
Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative? - Yahoo Finance
(REGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BI Asset Management Fondsmaeglerselskab A S Sells 2,968 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc (REGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Regeneron Pharmaceuticals (REGN) Leans On Pipeline Promise As Undervaluation Case Stays In Focus - simplywall.st
Regeneron (REGN) Advances Cemdisiran for Myasthenia Gravis with Regulatory Approvals - GuruFocus
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Regeneron's Applications for gMG Drug Accepted by FDA and EMA - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS) - The Globe and Mail
Regeneron highlights RNAi drug submissions, shares trade in Nasdaq range - AD HOC NEWS
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
2 Underrated Weight Loss Stocks to Buy and Hold - The Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Institutional Confidence - TradingKey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Regeneron (REGN) Gains Regulatory Milestones for Cemdisiran in g - GuruFocus
0.22%
3.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):